Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening

Digestive and Liver Disease

Volumn 48, Issue 5, 2016, Pages 542-551

  Alvarez Urturi, Cristina ^a   Andreu, Montserrat ^a   Hernandez, Cristina ^b   Perez Riquelme, Francisco ^c   Carballo, Fernando ^c   Ono, Akiko ^c   Cruzado, Jose ^c   Cubiella, Joaquín ^d   Hernandez, Vicent ^d   Mao, Carmen Gonzalez ^e   Perez, Elena ^f   Salas, Dolores ^f   Andrés, Mercedes ^f   Bujanda, Luis ^g   Portillo, Isabel ^h   Sarasqueta, Cristina ⁱ   Quintero, Enrique ^j   Morillas, Juan Diego ^k   Lanas, Angel ^l   Sostres, Carlos ^l   Augé, Josep Maria ^m   Castells, Antoni ^m   Bessa, Xavier ^a   more..

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c Consejería de Sanidad y Política Social ^*  (Spain)

^d SERGAS UVigo   (Spain)

^e Complexo Hospitalario Vigo ^*  (Spain)

^f Dirección General de Salud Pública ^*  (Spain)

^g UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^h Osakidetza Servicio Vasco de Salud   (Spain)

ⁱ HOSPITAL DONOSTIA   (Spain)

^j HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l UNIVERSITY OF ZARAGOZA   (Spain)

^m UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

Colorectal cancer screening; Cut off values

Indexed keywords

HEMOGLOBIN;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CANCER DIAGNOSIS; CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL TUMOR; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FECAL IMMUNOCHEMICAL TEST; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADENOMA; CARCINOMA IN SITU; CHEMISTRY; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; FECES; IMMUNOASSAY; IMMUNOCHEMISTRY; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE VALUE; SEX DIFFERENCE;

ADENOMA; AGE FACTORS; AGED; CARCINOMA IN SITU; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOASSAY; IMMUNOCHEMISTRY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 84975686317     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.02.001     Document Type: Article

References (48)

1. Torre L.A., Bray F., Siegel R.L., et al. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2015, 65:87-108.
2. Levin B., Lieberman D.A., McFarland B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA: A Cancer Journal for Clinicians 2015, 58:130-160.
3. Pignone M., Saha S., Hoerger T., et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2002, 137:96-104.
4. Rundle A.G., Lebwohl B., Vogel R., et al. Colonoscopic screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology 2008, 134:1311-1315.
5. Regula J., Rupinski M., Kraszewska E., et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. New England Journal of Medicine 2006, 355:1863-1872.
6. Mandel J.S., Bond J.H., Church T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. New England Journal of Medicine 1993, 328:1365-1371.
7. Hardcastle J.D., Chamberlain J.O., Robinson M.H., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348:1472-1477.
8. Atkin W.S., Edwards R., Kralj-Hans I., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010, 375:1624-1633.
9. Van Rossum L.G., van Rijn A.F., Laheij R.J., et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008, 135:82-90.
10. Chen L.-S., Yen A.M.-F., Fraser C.G., et al. Impact of faecal haemoglobin concentration on colorectal cancer mortality and all-cause death. BMJ Open 2013, 3:e003740.
11. Brenner H., Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. European Journal of Cancer 2013, 49:3049-3054.
12. Allison J.E., Fraser C.G., Halloran S.P., et al. Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver 2014, 8:117-130.
13. Lee J.K., Liles E.G., Bent S., et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Annals of Internal Medicine 2014, 60:171.
14. Hol L., van Leerdam M.E., van Ballegooijen M., et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2009, 59:62-68.
15. James P.D., Rabeneck L.Y.L. Regular screening with FOBT is associated with detection of colorectal cancer at an earlier stage: a population-based study. Gastroenterology 2012, 142:S768.
16. Wilschut J.A., Habbema J.D.F., van Leerdam M.E., et al. Fecal occult blood testing when colonoscopy capacity is limited. Journal of the National Cancer Institute 2011, 103:1741-1751.
17. Young G.P., Symonds E.L., Allison J.E., et al. Advances in fecal occult blood tests: the FIT revolution. Digestive Diseases and Sciences 2015, 60:609-622.
18. Omata F., Shintani A., Isozaki M., et al. Diagnostic performance of quantitative fecal immunochemical test and multivariate prediction model for colorectal neoplasms in asymptomatic individuals. European Journal of Gastroenterology and Hepatology 2011, 23:1036-1041.
19. Stegeman I., de Wijkerslooth T.R., Stoop E.M., et al. Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut 2014, 63:466-471.
20. Chen L.-S., Yen A.M.-F., Chiu S.Y.-H., et al. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncology 2011, 12:551-558.
21. Auge J.M., Pellise M., Escudero J.M., et al. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program. Gastroenterology 2014, 147. 628-36.e1.
22. Fraser C.G., Rubeca T., Rapi S., et al. Faecal haemoglobin concentrations vary with sex and age, but data are not transferable across geography for colorectal cancer screening. Clinical Chemistry and Laboratory Medicine 2014, 52:1211-1216.
23. McDonald P.J., Strachan J.A., Digby J., et al. Faecal haemoglobin concentrations by gender and age: implications for population-based screening for colorectal cancer. Clinical Chemistry and Laboratory Medicine 2012, 50:935-940.
24. Brenner H., Haug U., Hundt S. Sex differences in performance of fecal occult blood testing. American Journal of Gastroenterology 2010, 105:2457-2464.
25. Kapidzic A., van der Meulen M.P., Hol L., et al. Gender differences in fecal immunochemical test performance for early detection of colorectal neoplasia. Clinical Gastroenterology and Hepatology 2015, http://www.ncbi.nlm.nih.gov/pubmed/25724706.
26. Wong M.C.S., Ching J.Y.L., Chan V.C.W., et al. Factors associated with false-positive and false-negative fecal immunochemical test results for colorectal cancer screening. Gastrointestinal Endoscopy 2015, 81:596-607.
27. Stegeman I., de Wijkerslooth T.R., Stoop E.M., et al. Risk factors for false positive and for false negative test results in screening with fecal occult blood testing. International Journal of Cancer 2013, 133:2408-2414.
28. Chiang T.-H., Lee Y.-C., Tu C.-H., et al. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. Canadian Medical Association Journal 2011, 183:1474-1481.
29. Imperiale T.F., Glowinski E.A., Lin-Cooper C., et al. Tailoring colorectal cancer screening by considering risk of advanced proximal neoplasia. American Journal of Medicine 2012, 125:1181-1187.
30. Ferlitsch M., Reinhart K., Pramhas S., et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. Journal of the American Medical Association 2011, 306:1352-1358.
31. Von Karsa L., Patnick J., Segnan N., et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013, 45:51-59.
32. Quintero E., Castells A., Bujanda L., et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. New England Journal of Medicine 2012, 366:697-706.
33. Fraser C.G., Allison J.E., Halloran S.P., et al. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. Journal of the National Cancer Institute 2012, 104:810-814.
34. Grazzini G., Visioli C.B., Zorzi M., et al. Immunochemical faecal occult blood test: number of samples and positivity cut-off. What is the best strategy for colorectal cancer screening?. British Journal of Cancer 2009, 100:259-265.
35. Hol L., Wilschut J.A., van Ballegooijen M., et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. British Journal of Cancer 2009, 100:1103-1110.
36. Faivre J., Dancourt V., Manfredi S., et al. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme. Digestive and Liver Disease 2012, 44:700-704.
37. Faivre J., Dancourt V., Denis B., et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. European Journal of Cancer 2012, 48:2969-2976.
38. Rozen P., Liphshitz I., Barchana M. Follow-up of patients undergoing both semiquantitated immunochemical fecal occult blood and colonoscopy examinations. European Journal of Cancer Prevention 2012, 21:247-253.
39. Terhaar sive Droste J.S., Oort F.A., van der Hulst R.W.M., et al. Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiology, Biomarkers and Prevention 2011, 20:272-280.
40. Van Rossum L.G.M., van Rijn A.F., Laheij R.J.F., et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. British Journal of Cancer 2009, 101:1274-1281.
41. Guittet L., Bouvier V., Mariotte N., et al. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. International Journal of Cancer 2009, 125:1127-1133.
42. De Wijkerslooth T.R., Stoop E.M., Bossuyt P.M., et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. American Journal of Gastroenterology 2012, 107:1570-1578.
43. Wong M.C.S., Ching J.Y.L., Chan V.C.W., et al. Diagnostic accuracy of a qualitative fecal immunochemical test varies with location of neoplasia but not number of specimens. Clinical Gastroenterology and Hepatology 2015, http://www.ncbi.nlm.nih.gov/pubmed/25724708.
44. Haug U., Kuntz K.M., Knudsen A.B., et al. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. British Journal of Cancer 2011, 104:1779-1785.
45. Salas D., Vanaclocha M., Ibáñez J., et al. Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening. Cancer Causes and Control 2014, 25:985-997.
46. Steele R.J.C., McClements P., Watling C., et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 2012, 61:576-581.
47. Gill M.D., Bramble M.G., Rees C.J., et al. Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme. British Journal of Cancer 2012, 107:417-421.
48. Brenner H., Chang-Claude J., Seiler C.M., et al. Interval cancers after negative colonoscopy: population-based case-control study. Gut 2012, 61:1576-1582.